Dosing guidelines for fluconazole in patients with renal failure

Nephrology Dialysis Transplantation

Volumn 18, Issue 11, 2003, Pages 2227-2231

  Cousin, Lucile ^a   Le Berre, Marie ^a   Launay Vacher, Vincent ^a   Izzedine, Hassane ^a   Deray, Gilbert ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CAPD; CVVH; Fluconazole; Haemodialysis; Renal insufficiency

Indexed keywords

FLUCONAZOLE;

ABDOMINAL PAIN; AREA UNDER THE CURVE; CANDIDIASIS; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIARRHEA; DOSE KIDNEY FUNCTION RELATION; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DIALYSABILITY; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG URINE LEVEL; EDITORIAL; HEADACHE; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE DRUG DOSE; MULTIPLE DRUG DOSE; NAUSEA; OPTIMAL DRUG DOSE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RASH; VOMITING;

ANTIFUNGAL AGENTS; FLUCONAZOLE; HUMANS; KIDNEY FAILURE;

EID: 0242351701     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/gfg363     Document Type: Editorial

References (27)

1. Thomas AH. Suggested mechanisms for the antimycotic activity of the polyene antibiotics and the N-substituted imidazoles. J Antimicrob Chemother 1986; 17: 269-279
2. Van den Bossche H, Willemsens G, Cools W, Marichal P, Lauwers W. Hypothesis on the molecular basis of the antifungal activity of N-subsituted imidazoles and triazoles. Biochem Soc Trans 1983; 11: 665-667
3. Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol 1994; 46: 147-150
4. Blum RA, D'Andrea DT, Florentino BM et al. Increased gastric pH and bioavailability of fluconazole and ketoconazole. Ann Intern Med 1991; 114: 755-757
5. Grant SM, Clissold SP. Fluconazole. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial and systemic mycoses. Drugs 1990; 39: 877-916
6. Dudley MN. Clinical pharmacology of fluconazole. Pharmacotherapy 1990; 10: S141-S145
7. 14C]fluconazole in humans. Drug Metab Disp 1991; 19: 764-767
8. Humphrey MJ, Jevons S, Tarbit MH. Pharmacokinetic evaluation of UK-49.858, a metabolically stable triazole antifungal agent, in animals and humans. Antimicrob Agents Chemother 1985; 28: 648-653
9. Morera Y, Torres-Rodriguez JM, Catalan I, Granadero A, Josic Z, Alvarez-Lerma F. Candiduria in patients with urethral catheter admitted in intensive care unit. Etiology and in vitro susceptibility to fluconazole. Med Clin 2002; 118: 580-582
10. Safdar A, Chaturvedi V, Koll BS, Larone DH, Perlin DS, Armstrong D. Prospective, multicenter surveillance study of Candida glabrata: fluconazole and itraconazole susceptibility profiles in bloodstream, invasive, and colonizing strains and differences between isolates from three urban teaching hospitals in New-York City (Candida Susceptibility Trends Study, 1998 to 1999). Antimicrob Agents Chemother 2002; 46: 3268-3272
11. Fernandez Andreu CM, Pimentel Turino T, Martinez Machin G, Gonzalez Miranda M. Determination of the minimum inhibitory concentration of fluconazole against Cryptococcus neoformans. Rev Cubana Med Trop 1999; 51: 55-57
12. Ikemoto H, Watanabe K, Mori T. Clinical study of fluconazole on deep-seated fungal infections. Jap J Antibiotics 1989; 42: 63-116
13. Debruyne D, Ryckelynck JP. Clinical pharmacokinetics of fluconazole. Clin Pharmacokinet 1993; 24: 10-27
14. Toon S, Ross CE, Gokal R, Rowland M. An assessment of the effects of impaired renal function and haemodialysis on the pharmacokinetics of fluconazole. Br J Clin Pharmacol 1990; 29: 221-226
15. Oono S, Tabei K, Tetsuka T, Asano Y. The pharmacokinetics of fluconazole during haemodialysis in uraemic patients. Eur J Clin Pharmacol 1992; 42: 667-670
16. Launay-Vacher V, Storme T, Izzedine H, Deray G. Pharmacokinetic changes in renal failure. Presse Med 2001; 30: 597-604
17. Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of anti-retroviral drugs in haemodialysis. Kidney Int 2001; 60: 821-830
18. Bren A, Kandus A, Lindic J, Varl J. Fluconazole in the treatment of fungal infections in kidney-tranplanted patients. Transplant Proc 1992; 24: 2765-2766
19. Berl T, Wilner KD, Gardner M et al. Pharmacokinetics of fluconazole in renal failure. J Am Soc Nephrol 1995; 6: 242-247
20. Dahl NV, Foote EF, Searson KM et al. Pharmacokinetics of intraperitoneal fluconazole during continuous cycling peritoneal dialysis. Ann Pharmacother 1998; 32: 1284-1289
21. Levine J, Bernard DB, Idelson BA, Farnham H, Saunders C, Sugar AM. Fungal peritonitis complicating continuous ambulatory peritoneal dialysis: successful treatment with fluconazole, a new orally active antifungal agent. Am J Med 1989; 86: 825-827
22. Valtonen M, Tiula E, Neuvonen PJ. Effect of continuous veno-venous haemofiltration and haemodiafiltration of fluconazole in patients with acute renal failure. J Antimicrob Chemother 1997; 40: 695-700
23. Wolter K, Marggraf G, Dermouni H, Fritschke E. Elimination of fluconazole during continuous veno-venous haemodialysis (CVVHD). Eur J Clin Pharmacol 1994; 47: 291-292
24. Nicolau DP, Crowe H, Nightingale CH, Quintiliani R: Effect of continuous arteriovenous hemodiafiltration on the pharmacokinetics of fluconazole. Pharmacotherapy 1994; 14: 502-505
25. Pittrow L, Penk A. Dosage adjustment of fluconazole during continuous renal replacement therapy (CAVH, CVVH, CAVHD, CVVHD). Mycoses 1999; 42: 17-19
26. Kishino S, Koshinami Y, Hosoi T et al. Effective fluconazole therapy for liver transplant recipients during continuous hemodiafiltration. Ther Drug Monit 2001; 23: 4-8
27. Muhl E, Martens T, Iven H, Rob P, Bruch HP. Influence of continuous veno-venous haemodiafiltration and continuous veno-venous haemofiltration on the pharmacokinetics of fluconazole. Eur J Clin Pharmacol 2000; 56: 671-678